Price (90d)
$79.86Signal Score (90d)
40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $502.08M | $-729.31M | $-3.79 |
| 2024 | $221.90M | $-535.76M | $-2.88 |
| 2023 | $9.30M | $-643.20M | $-3.95 |
| 2022 | $77.65M | $-481.18M | $-3.35 |
| 2021 | $69.72M | $-562.54M | $-3.90 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $-0.67 per share
Typical surprise -20.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.78 vs $-0.58miss
- Thu, May 7$-0.84 vs $-0.68miss
- Tue, Feb 24$-1.00 vs $-0.71miss
- Wed, Oct 29$-0.95 vs $-0.88miss
- Tue, Aug 5$-0.95 vs $-0.83miss
- Tue, Apr 29$-0.88 vs $-1.00beat
Estimates and results for BBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
BBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (8)
- Newsglobenewswire.com·1d ago·Negative
… the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the pricing of a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.
View source ↗ - News (Marketaux)manilatimes.net·1d ago·Neutral
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder ., Aug. 13, 2026 (GLOBE NEWSWIRE) -- <em[+46 characters]
View source ↗ - Newsglobenewswire.com·1d ago·Negative
…aunch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will…
View source ↗ - Newszacks.com·4d ago·Neutral
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
View source ↗ - Newsseekingalpha.com·4d ago·Neutral
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline inves
View source ↗ - Newsseekingalpha.com·4d ago·Positive
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·4d ago·Negative
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
View source ↗ - Newsmarketbeat.com·4d ago·Positive
BridgeBio Pharma Q2 Earnings Call Highlights BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year.
View source ↗